Egetis Therapeutics has secured SEK 172 million in private placement and SEK 290 million in debt financing to advance the development of its lead candidate, Emcitate, targeting MCT8 deficiency.

Information on the Target

Egetis Therapeutics AB (publ) is an innovative pharmaceutical company specializing in the development of drugs for serious diseases with significant unmet medical needs, particularly within the orphan drug segment. The company is focused on late-stage development for commercializing its lead candidate, Emcitate, which targets patients diagnosed with monocarboxylate transporter 8 (MCT8) deficiency, a rare and debilitating disorder. Currently, Emcitate is undergoing a pivotal study as part of its regulatory submission processes in both the European Union and the United States.

On October 10, 2023, Egetis announced a secured financing strategy involving a private placement and debt financing. This move is aimed at bolstering the company’s financial resources to support the ongoing development and regulatory approvals required for Emcitate, and to solidify its commercial readiness to serve patients awaiting effective treatments.

Industry Overview in Sweden

The Swedish pharmaceutical industry is recognized for its significant contributions to global health, driven by a robust framework of research and development (R&D) and strong regulatory oversight. Sweden has established itself as a hu